Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Classificação em ações #33635
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Preço da ação
$0.03702159
Última sincronização: 2024-01-29
Valor de mercado
$7.21M
Variação (1 dia)
-3.08%
Variação (1 ano)
0.00%
País
AU
Negociar Antisense Therapeutics Limited (ANP)

Categoria

Histórico de preços das ações de Antisense Therapeutics Limited (ANP)
Preço de fecho mais alto: $0.04 em 2024-01-01

Preço de fecho mais baixo: $0.89 em 2001-12-01
Histórico de preços das ações da Antisense Therapeutics Limited de 2001 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2024 3.20%
2023 -37.05%
2022 -56.36%
2021 59.69%
2020 44.65%
2019 191.58%
2018 3.71%
2017 -27.93%
2016 -45.26%
2015 -30.97%
2014 -50.82%
2013 16.96%
2012 -52.56%
2011 252.85%
2010 -78.09%
2009 107.28%
2008 -31.61%
2007 18.43%
2006 15.79%
2005 -72.58%
2004 4.39%
2003 129.21%
2002 -69.82%
2001 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$171.67 -
DE
$161.44 23.08%
DE
$35.97 20.03%
JP
$225.32 37.71%
CH
$20.95 11.92%
IN